PF-06438179/GP1111: An Infliximab Biosimilar
- 87 Downloads
PF-06438179/GP1111 (Zessly®; Ixifi®) [hereafter referred to as GP1111] is a biosimilar of the reference monoclonal anti-TNF-α antibody infliximab, and is approved in the EU and USA for the same indications as the reference drug, including rheumatoid arthritis (RA), Crohn’s disease, ulcerative colitis (including paediatric ulcerative colitis in the EU), ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; GP1111 is also approved in Japan. GP1111 has similar physicochemical characteristics and pharmacodynamic properties to those of reference infliximab, and the pharmacokinetic similarity of the agents has been shown in healthy volunteers and patients with moderate-to-severe RA despite methotrexate therapy. GP1111 demonstrated clinical efficacy equivalent to that of reference infliximab in patients with moderate-to-severe RA, despite methotrexate therapy, and was generally well tolerated in this population. The tolerability, immunogenicity and safety profiles of GP1111 were similar to those of reference infliximab, and switching from reference infliximab to GP1111 had no impact on safety, efficacy or immunogenicity. The role of reference infliximab in the management of autoimmune inflammatory conditions is well established and GP1111 provides an effective biosimilar alternative for patients requiring infliximab therapy.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of GP1111 was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. Zaina T. Al-Salama is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 1.European Medicines Agency. Zessly 100 mg powder for concentrate for solution for infusion: summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 20 Sep 2018.
- 4.Alten R, Tseluyko V, Hala T, et al. Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab [abstract no. FRI0137]. Ann Rheum Dis. 2018;77(Suppl 1):612.Google Scholar
- 5.Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018. https://doi.org/10.1186/s13075-018-1646-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Cohen S, Kivitz AJ, Tee M, et al. A randomized, double-blind phase III study comparing the efficacy, safety and immunogenicity of PF-06438179/GP1111 (Ixifi™), an infliximab biosimilar, and infliximab reference product (Remicade®) in patients with moderate to severe active RA: results from week 54 to week 78 [abstract no. 2521]. Arthritis Rheumatol. 2018;70(Suppl 10).Google Scholar
- 7.US National Institutes of Health. ClinicalTrials.gov identifier NCT02222493. 2018. https://clinicaltrials.gov. Accessed 20 Sep 2018
- 8.European Medicines Agency. Assessment report: Zessly (international non-proprietary name: infliximab). 2018. http://www.ema.europa.eu. Accessed 20 Sep 2018.
- 9.Palaparthy R, Schmitt S, Rehman MI, et al. Incidence and impact of immunogenicity in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. [abstract no. P554]. J Crohns Colitis. 2018;12(Suppl 1):S386.Google Scholar